Group 1 - iREIT+HOYA Capital focuses on income-producing asset classes that provide sustainable portfolio income, diversification, and inflation hedging [1] - Companies with strong shareholder returns often possess moat-worthy attributes derived from scale and barriers to entry, particularly in industries like pharmaceuticals [2] Group 2 - The article emphasizes the importance of defensive stocks with a medium- to long-term investment horizon [2]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Merck & Co., Inc. related to misleading statements about Gardasil's expected revenue and demand in China, with a deadline for investors to seek lead plaintiff status in a federal securities class action by April 14, 2025 [2][4]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses exceeding $100,000 in Merck between February 3, 2022, and February 3, 2025, to discuss their legal rights [1]. - The complaint alleges that Merck and its executives violated federal securities laws by making false statements regarding Gardasil's revenue expectations and demand in China [4]. - The firm has recovered hundreds of millions of dollars for investors since its founding in 1995, indicating a strong track record in securities litigation [3]. Group 2: Financial Performance and Market Reaction - On February 4, 2025, Merck reported a 3% decline in GARDASIL/GARDASIL 9 sales to $8.6 billion and announced a temporary pause in shipments to China [5]. - Following the announcement, Merck's stock price fell by $9.05 per share, or 9.1%, closing at $90.74 per share [5]. Group 3: Class Action Details - The lead plaintiff in a class action is the investor with the largest financial interest who directs the litigation on behalf of the class [6]. - Any member of the putative class can move the court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [6].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Merck & Co., Inc. regarding a class action lawsuit related to misleading statements about the expected revenue from Gardasil sales, which has led to a significant decline in Merck's stock price [1]. Group 1: Allegations and Impact - The lawsuit alleges that Merck provided investors with material information indicating expected revenue of $11 billion from Gardasil sales by 2030, supported by optimistic forecasts about demand in China [1]. - On February 4, 2025, Merck announced it would not achieve the projected $11 billion in sales, citing a halt in shipments to China due to over-inflated inventories and lower-than-expected demand [1]. - Following this announcement, Merck's stock price dropped from $99.79 per share on February 3, 2025, to $90.74 per share on February 4, 2025, representing a decline of over 9% in one day [1]. Group 2: Next Steps for Shareholders - Shareholders who purchased shares of MRK during the specified class period are encouraged to register for the class action, with a deadline of April 14, 2025, to seek lead plaintiff status [2]. - Registered shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's progress [2]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [3]. - The firm seeks recovery for investors who suffered losses due to misleading statements or omissions that artificially inflated stock prices [3].

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Merck & Co., Inc. for alleged misrepresentations regarding the demand for its vaccine drug Gardasil in China, impacting investor confidence and inventory levels [1][2]. Group 1: Lawsuit Details - The lawsuit represents investors who purchased Merck securities between February 3, 2022, and February 3, 2025 [1]. - Allegations include that Merck lacked visibility into the demand for Gardasil in China, leading to inflated inventory levels at its distributor, Zhifei [2]. Group 2: Legal Process - Interested parties wishing to serve as lead plaintiff must file by April 14, 2025, with the role involving directing the litigation on behalf of the class [3]. - Shareholders can remain absent class members without taking action, and all representation is on a contingency fee basis, meaning no fees or expenses are required from shareholders [3]. Group 3: Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented large public and private pension funds [4]. - The firm has been recognized multiple times for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" and listed in The Legal 500 for sixteen consecutive years [4].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Merck To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Merck between February 3, 2022 and February 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Feb. 19, 2025 (GLOBE N ...

Core Viewpoint - A class action lawsuit has been filed against Merck & Co., Inc. for alleged violations of securities laws, specifically related to misleading statements about the demand for its product Gardasil in China and inflated inventory issues [1][4]. Group 1: Lawsuit Details - The lawsuit is based on violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1]. - Investors who purchased Merck's securities between February 3, 2022, and February 3, 2025, are encouraged to participate in the lawsuit [2]. - The class has not yet been certified, meaning potential participants are not currently represented by an attorney [3]. Group 2: Allegations Against Merck - The complaint alleges that Merck made false and misleading statements regarding its consumer activation and education efforts for Gardasil, particularly in China [4]. - The company was overly optimistic about Gardasil's demand while concealing negative facts about actual demand and inflated inventory held by its distributor, Zhifei [4]. - As a result of these misleading statements, investors suffered damages when the truth about Merck's situation was revealed [4].

NEW YORK, Feb. 18, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Merck & Co., Inc. ("Merck" or the "Company") (NYSE: MRK) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Merck investors who were adversely affected by alleged securities fraud between February 3, 2022 and February 3, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/merck-co-inc-lawsuit-submission-form? ...

NEW YORK, Feb. 16, 2025 /PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Merck & Co., Inc. ("Merck" or "the Company") (NYSE: MRK) and certain of its officers.Class DefinitionThis lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Merck securities betwe ...

SAN DIEGO, Feb. 15, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Merck & Co., Inc. (NYSE: MRK) securities between February 3, 2022 and February 3, 2025, both dates inclusive (the "Class Period"), have until April 14, 2025 to seek appointment as lead plaintiff of the Merck class action lawsuit.  Captioned Cronin v. Merck & Co., Inc., No. 25-cv-01208 (D.N.J.), the Merck class action lawsuit charges Merck and certain of Merck's top executives with violations o ...

SAN DIEGO, Feb. 14, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Merck & Co., Inc. (NYSE: MRK) securities between February 3, 2022 and February 3, 2025. Merck is a global healthcare company.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Allegations: Robbins LLP is Investigating Allegations that Merck & Co., Inc. (MRK) Misled Investors Regarding ...